Friday, March 16, 2007

Epiphany Biosciences Discovers $36M

San Francisco-based Epiphany Biosciences has scored $36M in a Series A funding round, the firm said this week. Epiphany Biosciences said that it has a therapeutic focus on discovering and developing anti-infective agents. The firm's funding was led by Wexford Capital, and also included Windsor Bay Capital, Global Trust Ventures Management, and CDIB BioScience Venture Management and other investors. Epiphany's lead candidate is an anti-viral targeted against shingles. More information »